DESCRIPTION:

This presentation will discuss the biology of T cell engagers, clinical pharmacology lessons, recent examples of advancing TCE programs, and look at the future immune cell engager landscape.

LEARNING OBJECTIVES:

• Understand the path and evolution of select TCE’s
• Understand innovative approaches to FIH dose selection for TCE’s and how they differ from traditional oncology therapeutics
• Understand the future landscape of immune cell engagers and the particular challenges they seek to solve.